Reni Benjamin has given his Buy rating due to a combination of factors that highlight Iovance Biotherapeutics’ promising investment potential. The company has demonstrated strong performance ...
Robust balance sheet with cash, cash equivalents and investments of $199.6 million as of September 30, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, Nov. 12, 2024 (GLOBE ...
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback